Please do not leave this page until complete. This can take a few moments.
“Central Massachusetts will complement the existing strengths in Greater Boston, accelerating the momentum for the Commonwealth to lead the emerging biomanufacturing sector in the U.S.,” the report reads.
DEX Agent is a new Wyebot product that can be loaded onto Intel-based devices, allowing IT workers to monitor WiFi user experience and detect issues with connectivity
UMass Memorial Medical Center’s emergency room in Worcester last year quietly became the first level-one trauma center in the United States to implement KATE AI.
Hodge takes the role at a time where colleges across the country are facing the prospect of declining enrollment.
Central Massachusetts universities are implementing AI technology into courses and trying to address concerns for faculty and students.
Less than four months after hiring its first CEO in company history, Natick-based biopharmaceutical company AffyImmune Therapeutics has a new leader.
The Milford production line in the largest-ever expansion for global biopharmaceutical manufacturer Rentschler Biopharma is now fully operational, a major milestone as the Germany-based company ramps up its contract work.
House Democrats plan Wednesday to mount a late-session effort to prohibit cell phone carriers and other data providers from collecting or selling location information when Bay Staters seek abortions and other sensitive health care.
Come fall, students at Quinsigamond Community College in Worcester will have the opportunity to earn the institution’s new Automation Robotics Manufacturing Technology certificate, a program aimed at preparing students for entry-level positions in
Marlborough medical device manufacturing firm Boston Scientific looks to soon add stroke prevention treatment to its portfolio, as the manufacturer has entered into a $1.16 billion agreement to purchase California-based medical device company Silk
The oral tablet, known as ALZ-801 or Valiltramiprosate, intends to block the formation of neurotoxic molecules in the brain believed to be drivers of the disease.
A New York nonprofit has donated $2.2 million to UMass Chan Medical School in Worcester to help fund gene therapy research on a rare and fatal genetic disorder largely impacting children and young adults.
Despite claims of a pause, work at the site appears to be ongoing.
UMass Chan Medical School has unveiled its $350-million New Education and Research Building designed to advance disease research while UMass Memorial Health is in the midst of constructing a $125-million, 72-bed acute care facility.
The company was one of eight fusion-related companies selected by the DOE to receive a total of $46 million, as part of the department’s Milestone-Based Fusion Development Program
The eight-week pilot program at WPS concluded in May.